Myrcludex B | German Center for Infection Research

Skip to main content

Short description

Myrcludex B is a drug against B and hepatitis D.

Detailed description

The medication developed by DZIF scientists prevents B viruses and hepatitis D viruses from entering liver cells. of hepatitis B and hepatitis D presents the most serious form of viral hepatitis and was untreatable until then. Myrcludex B is a substance well tolerated by humans and it prevents viral reproduction.

Developing Medication

Developing a new medication usually takes more than ten years. Out of the several thousand substances investigated in basic and pre-clinical research, only one or two candidates are approved by

Heidelberg

Translational Virology

Besides analysing replication mechanisms of hepatitis B (HBV) and D (HDV) viruses, the focus of Professor Stephan Urban and his team is to develop new drugs against these pathogens. With Myrcludex B, which blocks the entry of viruses into the liver cell, a substance has already been taken from basic ...

Prof Stephan Urban

First Professor of Translational Virology

It all began 20 years ago with Pekin duck breeding in Kirchheim near Heidelberg. At the time, duck was the model of choice for hepatitis B research, which Stephan Urban also used to discover a peptide

Ralf Bartenschlager, Heidelberg

Award winner, without airs and graces

The hepatitis C research success story is also his story: Ralf Bartenschlager, a virologist at the Heidelberg Medical Faculty of Heidelberg University, has been researching the hepatitis C virus for

Myrcludex B inhibits also the entry of Hepatitis D (HDV) into the liver cell

Myrcludex B: Priority for the new hepatitis D virus entry inhibitor

The European Medicines Agency (EMA) has granted “PRIME eligibility” to Myrcludex B, and will provide priority support for its further drug development. The hepatitis B and D virus entry inhibitor was

No entry for Hepatitis D viruses (red; left) in hepatocytes with Myrcludex B (right).

Myrcludex B: First-in-class drug for the treatment of hepatitis B and D

DZIF scientists at the Heidelberg University Hospital developed a virus blocker against hepatitis B and D, which has been successful in two clinical trials

Around 350 million people suffer from

World Hepatitis Day

NOhep … for a world without hepatitis

Today’s World Hepatitis Day sets an ambitious goal: to eliminate viral hepatitis, especially hepatitis B and C, from the planet by 2030. Germany has also joined this international campaign. Scientists

Preisträger 2014

The first ever DZIF prize goes to a hepatitis researcher

(26/11/2014) Virologist Stephan Urban from the University of Heidelberg will receive the DZIF Prize for Translational Infection Research, worth 5000 Euros. It will be awarded for the first time at the